Variant
FLT3 ITD & Y842C
CI-VAR-00002047Explore in graph →CIViC 3210
Curated evidence
Evidence by cancer (4 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 29187377
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Acute Myeloid Leukemia4 | ||||||||
| FLT3 ITD & Y842C | FLT3 Inhibitor FF-10101 Succinate | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID9082By assessing cell viability using MTS assay, FF-10101 showed growth inhibitory effects on FLT3-ITD with Y842C mutation expressing 32D cells(Figure 3A). Consistently, FF-10101 potently inhibited FLT3 p… (full text at CIViC) PMID 29187377 · Yamaura et al., 2018 · Open in CIViC | civic |
| FLT3 ITD & Y842C | Ponatinib + SorafenibSubstitutes | Predictive | D | Supports Resistance | 4 | submitted | EID8895Proliferation of Ba/F3 cells with FLT3 double mutations was studied for the activity of ponatinib and sorafenib. Compared to control cells with native FLT3-ITD mutant (IC50: 3.0nM), cells with double … (full text at CIViC) PMID 23430109 · | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available